Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation and Depletion (2016 - 2017)

Intellia Therapeutics (NTLA) has disclosed Depreciation and Depletion for 3 consecutive years, with $660000.0 as the latest value for Q1 2017.

  • On a quarterly basis, Depreciation and Depletion rose 252.94% to $660000.0 in Q1 2017 year-over-year; TTM through Mar 2017 was $1.6 million, a 246.48% increase, with the full-year FY2017 number at $3.0 million, up 172.73% from a year prior.
  • Depreciation and Depletion was $660000.0 for Q1 2017 at Intellia Therapeutics, up from $401000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $660000.0 in Q1 2017 to a low of $33000.0 in Q1 2015.
  • A 3-year average of $228888.9 and a median of $187000.0 in 2016 define the central range for Depreciation and Depletion.
  • Biggest YoY gain for Depreciation and Depletion was 466.67% in 2016; the steepest drop was 176.04% in 2016.
  • Intellia Therapeutics' Depreciation and Depletion stood at $104000.0 in 2015, then surged by 285.58% to $401000.0 in 2016, then soared by 64.59% to $660000.0 in 2017.
  • Per Business Quant, the three most recent readings for NTLA's Depreciation and Depletion are $660000.0 (Q1 2017), $401000.0 (Q4 2016), and $265000.0 (Q3 2016).